News & Events zu Aptevo Therapeutics Inc (APVO)APVOAptevo Therapeutics Inc

Selling Stockholders Plan to Sell 6.44M Shares of Common Stock

This filing relates to the offer and sale from time to time by the selling stockholders of up to 6.44M shares of common stock. The company is not selling any shares under this prospectus and will not receive any of the proceeds from the sale of shares by the selling stockholders.

Aptevo Therapeutics Signs Warrant Inducement Agreements, Expected to Raise $4.5M

Aptevo Therapeutics announced it has entered into warrant inducement letter agreements with certain holders of its existing common warrants, pursuant to which such holders have agreed to exercise in full for cash their Existing Warrants to purchase up to an aggregate of 254,922 shares of common stock of the company at a reduced exercise price of $4.03 per share. In consideration for such cash exercises, the company will issue new unregistered common stock purchase warrants to purchase up to an aggregate of 1,274,610 shares of common stock at an exercise price of $4.03 per share. The Inducement Warrants will be exercisable on or after the date on which the company obtains the required stockholder approval and will expire five years after their initial exercise date. Separately, pursuant to a securities purchase agreement, the company agreed to sell to certain purchasers in a private placement up to 861,708 unregistered shares of common stock at a purchase price of $4.03 per share, together with common stock purchase warrants to purchase up to 4,308,540 shares of common stock at an exercise price of $4.03 per share. The Pre-Funded Warrants will be exercisable immediately and will expire upon exercise in full, and the Common Warrants will be exercisable on or after the date on which the company obtains the required stockholder approval and will expire five years after their initial exercise date. The aggregate gross proceeds from the transactions described herein are expected to total approximately $4.5M, before deducting placement agent fees and expenses. The transactions are expected to close on or about August 13, subject to satisfaction of customary closing conditions. Roth Capital Partners is acting as the company's exclusive placement agent in connection with these transactions.

Aptevo Therapeutics Unveils New Solid Tumor Strategy

Aptevo Therapeutics announced a new solid tumor strategy designed to fight cancer on multiple fronts. The Company has filed a patent application covering a proprietary Nectin-4 x PD-L1 dual-targeting backbone designed to strengthen Aptevo's oncology pipeline, expand partnering opportunities and support multiple therapeutic approaches from a single platform-derived innovation. For Aptevo, the filing helps secure the engine behind that strategy. Instead of pursuing one product built for one use, the filing will protect a backbone that may be adapted into multiple cancer-fighting approaches. That gives Aptevo more ways to advance its own pipeline, expands opportunities to work with large pharmaceutical companies and brings new thinking to the challenges of treating solid tumors.